Indian J Pharm Close
 

Figure 3: Effect of PECB pretreatment on scopolamine-induced changes on in vivo antioxidant parameters. (a) Lipid peroxidation, (b) nitric oxide, (c) superoxide dismutase, (d) catalase, (e) glutathione. Values are expressed as mean ± standard error of the mean (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 compared with normal control group; # P < 0.05, ##P < 0.01, ###P < 0.001 compared with scopolamine-treated group

Figure 3: Effect of PECB pretreatment on scopolamine-induced changes on<i> in vivo </i>antioxidant parameters. (a) Lipid peroxidation, (b) nitric oxide, (c) superoxide dismutase, (d) catalase, (e) glutathione. Values are expressed as mean ± standard error of the mean (<i>n</i> = 6). *<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001 compared with normal control group; #<i> P </i>< 0.05, ##<i>P</i> < 0.01, ###<i>P</i> < 0.001 compared with scopolamine-treated group